Adamis Pharmaceuticals Licenses 3M's Dry Powder Inhaler Technology
Adamis Pharmaceuticals agrees to license and potentially acquire 3M's Taper Dry Powder Inhaler technology.
The biopharmaceutical company Adamis Pharmaceuticals has formalized an agreement with 3M to exclusively license and, with additional payment, fully acquire 3M's Taper Dry Powder Inhaler (DPI) technology under development for the treatment of asthma and chronic obstructive pulmonary disease. As a part of the agreement, Adamis will obtain worldwide rights to use this platform technology in all indications in the dry-powder inhalation field. The design uses proprietary 3M technology to store API on a microstructured carrier tape. 3M will supply the drug-delivery tape for the platform to Adamis under a separate supply agreement.
Under the terms of the agreement, Adamis made an initial payment to exclusively license the Taper technology through Dec. 31, 2013, and upon payment of an additional amount before Dec. 31, 2013, will fully acquire the Taper technology.
Source: Adamis Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
